Education
This week on This Week in Diabetes & Endocrinology, from Hormone Insight: the
first large phase 3 trial of an oral GLP-1, orforglipron, in adults with type 2
diabetes and obesity (ATTAIN-2, Lancet). The headline is not the size of the
weight loss. It is the word oral.
Also this week:
- A 112,000-patient ACP network meta-analysis that keeps semaglutide and
tirzepatide on top for both weight loss and cardiovascular outcomes
- A provocative real-world comparison of bariatric surgery versus semaglutide
in fatty liver disease
- The 2026 ADA Standards of Care, which make cardiovascular and kidney
protection a co-primary goal alongside A1C
- A Hormone Classic revisit of UKPDS that explains why that shift had to happen
One question runs through all of it: does this change Monday clinic?
Chapters
00:00 Cold open
00:42 This week
01:13 Trial of the Week: orforglipron (ATTAIN-2)
04:29 Quick Hit: ACP weight-loss drug meta-analysis
05:21 Quick Hit: surgery vs semaglutide (MASLD)
06:21 Guideline & FDA Watch: 2026 ADA Standards
07:27 Hormone Classics: UKPDS
08:26 The Bottom Line
08:57 Sign-off
References and written summary: hormoneinsight.com/[slug]
For healthcare professionals. Educational, not individual medical advice.
Subscribe for a new episode every Saturday.
#diabetes #endocrinology #GLP1 #obesity #ADA2026